Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 135Observational 4Expanded_access 2

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Carcinoma, Renal Cell 2Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Everolimus × Clear all
NCT02184416 2026-02-27

ADONIS

Pfizer

Completed
554 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02264665 2023-11-13

OPALINE

Pfizer

Completed
144 enrolled 26 charts

Adenoma, Islet Cell

NCT01390519 2016-01-13

OSAT

Novartis

Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02023359 2015-12-29

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Novartis

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡